Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Rothfeld

Clinical Cardiac Electrophysiology Bradenton, FL Medical Doctor

NPI 1811973001 CMS profile 785200

316 Manatee Ave W, Bradenton, FL 34205

Open in the dashboard

General payments

$5,749

104 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$46,164 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Jeffrey Rothfeld of Bradenton, FL is reported in the CMS Open Payments database as having received $5,749 across 104 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $46,164 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 23rd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,966 30
2024 General $179 7
2023 General $222 11
2022 General $151 8
2021 General $336 16
2020 General $120 8
2019 General $1,775 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Rothfeld
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Jeffrey Rothfeld were reported at $2,966. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Jeffrey Rothfeld Clinical Cardiac Electrophysiology median Middle half National median
2019 $1,775 $2,361 $585–$8,260 $163
2020 $120 $993 $247–$4,351 $114
2021 $336 $1,185 $326–$4,739 $132
2022 $151 $2,073 $554–$6,789 $149
2023 $222 $2,568 $759–$8,159 $160
2024 $179 $2,557 $703–$7,403 $164
2025 $2,966 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $4,365 46 payments
  2. Biosense Webster, Inc. $229 10 payments
  3. Sanofi-Aventis U.S. LLC $190 9 payments
  4. Alnylam Pharmaceuticals Inc. $173 2 payments
  5. Abbott Laboratories $114 1 payment
  6. Novartis Pharmaceuticals Corporation $80 4 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $76 1 payment
  8. Novo Nordisk Inc $60 3 payments
  9. Inari Medical, Inc. $49 2 payments
  10. Cardinal Health 200, LLC $43 3 payments
  11. Other $370 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,094 9 payments
  2. Food and Beverage $2,636 94 payments
  3. Education $18 1 payment
Products named General payments · program years 2019–2025
  1. EMBLEM $1,361 3 payments
  2. General - Structural Heart $1,258 5 payments
  3. INGEVITY+ $1,068 7 payments
  4. Carto 3 $205 9 payments
  5. RESONATE $157 4 payments
  6. AMVUTTRA $146 1 payment
  7. MitraClip $114 1 payment
  8. RESONATE EL ICD VR $112 6 payments
  9. General - Therapies $97 2 payments
  10. PRALUENT $96 5 payments
  11. Other $1,234 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

9,567

Median for Cardiology: 2,533

Drug cost

$1,870,104

Median for Cardiology: $485,213

Branded share of claims

25.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 627 $696,178
Xarelto Rivaroxaban Brand 312 $344,981
Repatha Sureclick Evolocumab Brand 213 $215,461
Entresto Sacubitril/Valsartan Brand 174 $212,263
Multaq Dronedarone Hcl Brand 114 $156,260
Jardiance Empagliflozin Brand 58 $57,323
Praluent Pen Alirocumab Brand 31 $33,287
Flecainide Acetate Generic 318 $14,980
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 53 $13,846
Vascepa Icosapent Ethyl Brand 20 $10,379

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$284,744

Medicare's payments for the services billed

Medicare patients

1,888

Average age 78

Services billed

5,711

945 women, 943 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Arthritis 57%
Atrial fibrillation 46%
Chronic kidney disease 40%
Diabetes 33%
Heart failure 33%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $50
$50 114 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $18
$18 627 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record